Chiesi Brasil

Chiesi Brasil company information, Employees & Contact Information

Explore related pages

Related company profiles:

O grupo Chiesi, uma empresa farmacêutica ética, com 80 anos dedicados à pesquisa e ao desenvolvimento de medicamentos e novas tecnologias, é hoje uma das principais indústrias farmacêuticas da Europa, contando com uma extensa linha de produtos em diversos segmentos terapêuticos. Com sede em Parma, Itália, o grupo opera em todos continentes, com 22 filiais diretas, 3 plantas de produção (Itália, França e Brasil) e 4 centros de pesquisa e desenvolvimento de novos produtos e tecnologias (Itália, França, Estados Unidos e Inglaterra). A subsidiária Chiesi Farmacêutica Ltda é responsável pelas operações no Brasil desde 1976, oferecendo, aos profissionais de saúde e pacientes, medicamentos com a qualidade e confiabilidade reconhecidas em todo o mundo. Disponibilizamos recursos importantes para a terapêutica medicamentosa de doenças relacionadas às diversas especialidades como: doenças do trato respiratório (asma e doença pulmonar obstrutiva crônica); doenças alérgicas (rinites e urticária), cardiovasculares (hipertensão e angina), distúrbios metabólicos (dislipidemias), músculo-esqueléticas e suplementos com poliaminoácidos. Além de tecnologias que facilitam a vida dos pacientes, como dispositivos inalatórios e espaçadores para a administração de medicamentos utilizados por via inalatória. Atualmente o Grupo Chiesi, conta com mais de 3.000 funcionários em todo o mundo, sendo aproximadamente 350 no Brasil e, destes, 140 dedicam-se exclusivamente à divulgação científica para mais de 30.000 médicos no Brasil. Nossas instalações compreendem uma fábrica certificada pela ANVISA e Comunidade Européia, localizada no município de Santana de Parnaíba, além do escritório central em São Paulo.

Company Details

Employees
408
Founded
-
Address
Rua Dr. Rubens Gomes Bueno, 691, 14° Andar,brazil
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
São Paulo, Sao Paulo
Looking for a particular Chiesi Brasil employee's phone or email?

Chiesi Brasil Questions

News

Chiesi Farmaceutici and Samay Announce Collaboration to Advance Early Detection of Small Airway Disease - Morningstar

Chiesi Farmaceutici and Samay Announce Collaboration to Advance Early Detection of Small Airway Disease Morningstar

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU - Yahoo Finance

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU Yahoo Finance

Chiesi Global Rare Diseases Announces Multiple Presentations at 21st Annual WORLDSymposium™ Research Meeting - PR Newswire

Chiesi Global Rare Diseases Announces Multiple Presentations at 21st Annual WORLDSymposium™ Research Meeting PR Newswire

Optimizing the CHF6523 Isocoumarin Core Scaffold: From the Preclinical Stage to Large-Scale Production - ACS Publications

Optimizing the CHF6523 Isocoumarin Core Scaffold: From the Preclinical Stage to Large-Scale Production ACS Publications

Chiesi Announces FDA Acceptance of New Drug Application for its Triple Combination Inhaler for the Maintenance Treatment of Asthma - Yahoo Finance

Chiesi Announces FDA Acceptance of New Drug Application for its Triple Combination Inhaler for the Maintenance Treatment of Asthma Yahoo Finance

Chiesi: Industry-leading respiratory health, rare diseases, and speciality care solutions - Innovation News Network

Chiesi: Industry-leading respiratory health, rare diseases, and speciality care solutions Innovation News Network

Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease - ACS Publications

Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease ACS Publications

How Chiesi is walking the walk on pharma sustainability - pharmaphorum

How Chiesi is walking the walk on pharma sustainability pharmaphorum

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy - Business Wire

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy Business Wire

Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - GlobeNewswire

Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc GlobeNewswire

Chiesi launches ‘The Impulse’ to drive innovation and collaboration in healthcare - Innovation News Network

Chiesi launches ‘The Impulse’ to drive innovation and collaboration in healthcare Innovation News Network

Chiesi's international growth continues - PR Newswire

Chiesi's international growth continues PR Newswire

Chiesi Group announces performance growth in 2020 - GlobeNewswire

Chiesi Group announces performance growth in 2020 GlobeNewswire

Chiesi Global Rare Diseases Announces Publication of Results from Phase 3 BRIGHT Study of ELFABRIO® (pegunigalsidase alfa-iwxj) in Fabry Disease - PR Newswire

Chiesi Global Rare Diseases Announces Publication of Results from Phase 3 BRIGHT Study of ELFABRIO® (pegunigalsidase alfa-iwxj) in Fabry Disease PR Newswire

Chiesi Global Rare Diseases Launches “Rethink Acromegaly” Campaign to Provide Important Disease Education and Support to the Acromegaly Community - Yahoo Finance

Chiesi Global Rare Diseases Launches “Rethink Acromegaly” Campaign to Provide Important Disease Education and Support to the Acromegaly Community Yahoo Finance

Design, Synthesis, and Activity of a Novel Series of Pyridazine-Based ALK5 Inhibitors - ACS Publications

Design, Synthesis, and Activity of a Novel Series of Pyridazine-Based ALK5 Inhibitors ACS Publications

Chiesi Global Rare Diseases Announces U.S. Networkwide Sponsorship of BioInnovation Labs - PR Newswire

Chiesi Global Rare Diseases Announces U.S. Networkwide Sponsorship of BioInnovation Labs PR Newswire

Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders - PR Newswire

Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders PR Newswire

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease - PR Newswire

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease PR Newswire

Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support - PR Newswire

Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support PR Newswire

Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020 - PR Newswire

Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020 PR Newswire

Chiesi Global Rare Diseases Announces Health Canada - GlobeNewswire

Chiesi Global Rare Diseases Announces Health Canada GlobeNewswire

Chiesi USA Appoints Martin Marciniak as VP - citybiz

Chiesi USA Appoints Martin Marciniak as VP citybiz

Rare diseases must remain a political priority in the EU and beyond - The Parliament Magazine

Rare diseases must remain a political priority in the EU and beyond The Parliament Magazine

Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease - PR Newswire

Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease PR Newswire

Top Chiesi Brasil Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant